Mark L. Chapman
Pfizer
10 Papers
23 Citations
Mark L. Chapman is an academic researcher from Pfizer. The author has contributed to research in topics: Sodium channel & Sodium channel blocker. The author has an hindex of 7, co-authored 10 publications.
Chat about Author
Papers
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat
Michael F. Jarvis,Prisca Honore,Char Chang Shieh,Mark L. Chapman,Shailen K. Joshi,Xu Feng Zhang,Michael E. Kort,William A. Carroll,Brian E. Marron,Robert N. Atkinson,James Thomas,Dong Liu,Michael J. Krambis,Yi Liu,Steve McGaraughty,Katharine L. Chu,Rosemarie Roeloffs,Chengmin Zhong,Joseph P. Mikusa,Gricelda Hernandez,Donna M. Gauvin,Carrie Wade,Chang Zhu,Madhavi Pai,Marc J. C. Scanio,Lei Shi,Irene Drizin,Robert J. Gregg,Mark A. Matulenko,Ahmed A. Hakeem,Michael L. Gross,Matthew D. Johnson,Kennan C. Marsh,P. Kay Wagoner,James P. Sullivan,Connie R. Faltynek,Douglas S. Krafte +36 more
TL;DR: A-803467 is found, a sodium channel blocker that potently blocks tetrodotoxin-resistant currents and the generation of spontaneous and electrically evoked action potentials in vitro in rat dorsal root ganglion neurons and produces significant antinociception in animal models of neuropathic and inflammatory pain.
541
Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels
Ken McCormack,Sonia Santos,Mark L. Chapman,Douglas S. Krafte,Brian E. Marron,Christopher William West,Michael J. Krambis,Brett M Antonio,Shannon G. Zellmer,David Printzenhoff,Karen Padilla,Zhixin Lin,P. Kay Wagoner,Nigel Alan Swain,Stupple Paul Anthony,Marcel J. de Groot,Richard P. Butt,Neil A. Castle +17 more
TL;DR: A new class of subtype selective small molecule sodium channel inhibitors that interact with a region of the channel that controls voltage sensitivity is described, which may enable development of selective therapeutic interventions with reduced potential for toxicity.
Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release
Aristos J. Alexandrou,Adam R. Brown,Mark L. Chapman,Mark Estacion,Jamie Turner,Malgorzata A. Mis,Anna Wilbrey,Elizabeth C. Payne,Alex Gutteridge,Peter J. Cox,Rachel Doyle,David Printzenhoff,Zhixin Lin,Brian E. Marron,Christopher William West,Nigel Alan Swain,R. Ian Storer,Stupple Paul Anthony,Neil A. Castle,James A. Hounshell,Mirko Rivara,Andrew D. Randall,Sulayman D. Dib-Hajj,Douglas S. Krafte,Stephen G. Waxman,Manoj K. Patel,Richard P. Butt,Edward B. Stevens +27 more
TL;DR: It is reported that Nav1.7 is the predominant functional TTX-sensitive Nav in mouse and human nociceptors and contributes to the initiation and the upstroke phase of the nOCiceptor action potential, and a role for Nav 1.7 in influencing synaptic transmission in the dorsal horn of the spinal cord as well as peripheral neuropeptide release in the skin is confirmed.
Recent progress in sodium channel modulators for pain.
Sharan K. Bagal,Mark L. Chapman,Brian E. Marron,Rebecca L. Prime,R. Ian Storer,Nigel Alan Swain +5 more
TL;DR: Emerging clinical data combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery.
165
The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons.
Xin Su,Neil A. Castle,Brett Antonio,Rosemarie Roeloffs,James B. Thomas,Douglas S. Krafte,Mark L. Chapman +6 more
TL;DR: It is suggested that TTX-r sodium channels can be inhibited by many &kgr;-ORAs via an opioid receptor-independent mechanism and sodium channel block may still contribute to the antinociceptive effects of this class of compounds.
13